Transforming Anxiety & Mood Disorder Therapeutics: Advancing GlyphAgo™ (SPT 320), SPT 300, & SPT 348 in Next Generation Neuropsychiatric Care
- Advancing clinically validated mechanisms such as allopregnanolone, agomelatine and non hallucinogenic neuroplastogens through the Glyph™ platform, which overcomes limitations like low oral bioavailability, hepatotoxicity and poor PK profiles
- Enabling safer, more predictable anxiolytic and antidepressant activity by rerouting drug absorption through intestinal lymphatics, reducing liver exposure and supporting therapeutic plasma levels at lower doses, as demonstrated in early studies of GlyphAgo™ (SPT 320)
- Positioning SPT 300, an oral allopregnanolone prodrug, as a potential new option for major depressive disorder by unlocking a previously IV only mechanism through improved systemic exposure and tolerability
- Expanding treatment reach with SPT 348, a next generation non hallucinogenic neuroplastogen aimed at mood and neuropsychiatric disorders, designed to improve pharmacokinetics and tolerability while maintaining circuit modulating effects